Biomarkers In Retinitis Pigmentosa (BIRP)
BIRP
1 other identifier
observational
100
1 country
1
Brief Summary
In this study, markers of oxidative stress will be measured in the aqueous humour and plasma of RP patients compared to controls.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Sep 2013
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2013
CompletedFirst Submitted
Initial submission to the registry
September 20, 2013
CompletedFirst Posted
Study publicly available on registry
September 24, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2017
CompletedAugust 16, 2017
August 1, 2017
3.8 years
September 20, 2013
August 14, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Aqueous levels of markers of oxidative stress in patients with RP and controls.
2 years
Study Arms (2)
RP patients
Retinitis Pigmentosa patients
Controls
Patients who will be undergoing surgery for macular hole, epiretinal membrane, or vitreomacular traction, patients who have a retinal detachment , patients with neovascular age related macular degeneration and patients with diabetic retinopathy.
Interventions
Aqueous Samples will be collected for measurement of biomarkers
Eligibility Criteria
Retinitis Pigmentosa patients and Controls
You may qualify if:
- Signed informed consent and authorization of use and disclosure of protected health information
- Age more than or equal to 18 years
- For the study group, patients diagnosed with Retinitis Pigmentosa by the investigators
- For the control group, patients undergoing vitreoretinal surgery for macular hole, epiretinal membrane, vitreomacular traction, retinal detachment, neovascular Age-related Macular Degeneration (AMD) and Diabetic Retinopathy will be eligible
You may not qualify if:
- Patients with active or suspected ocular or periocular infection
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Wilmer Eye Institute
Baltimore, Maryland, 21287, United States
Biospecimen
Anterior Chamber fluid from the eye
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Peter Campochiaro, MD
Johns Hopkins University
Study Design
- Study Type
- observational
- Observational Model
- CASE CONTROL
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 20, 2013
First Posted
September 24, 2013
Study Start
September 1, 2013
Primary Completion
June 1, 2017
Study Completion
July 1, 2017
Last Updated
August 16, 2017
Record last verified: 2017-08
Data Sharing
- IPD Sharing
- Will not share